Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00619385 · ClinicalTrials.gov registry record · Phase 1
A Safety and Pharmacokinetic Study of Proellex®
A Phase 1 study, sponsored by Repros Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 25
- Enrollment target
NCT00619385: Completed Phase 1 study, sponsored by Repros Therapeutics.
NCT00619385 is a Phase 1 study that has completed, run by Repros Therapeutics. The registered enrollment target is 25 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (58% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00619385, a Phase 1 study, has completed, sponsored by Repros Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 25 participants
- Enrollment target
Study Summary
Dose escalating study of 7 daily doses of Proellex at 100 mg, 150 mg and 200 mg
Primary Outcome
To determine the safety and PK properties of 100 mg, 150 mg and 200 mg of Proellex® taken for seven days by healthy adult female subjects.
Interventions
- DRUG Proellex
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2008-02 |
| Est. Completion | 2008-10 |
| Phase | Phase 1 |
What the finished NCT00619385 record still lists
NCT00619385 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 25 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (58% lower).
The record links to 0 conditions, and to 1 intervention - of which Proellex is the first listed.
NCT00619385 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00619385 about?
NCT00619385 is a clinical study titled "A Safety and Pharmacokinetic Study of Proellex®". Dose escalating study of 7 daily doses of Proellex at 100 mg, 150 mg and 200 mg
What is the current status of trial NCT00619385?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 25 participants. The study started on 2008-02. Estimated completion is 2008-10.
What interventions are being tested in trial NCT00619385?
The interventions under investigation include: Proellex (DRUG).
Who is sponsoring clinical trial NCT00619385?
This trial is sponsored by Repros Therapeutics, which has 50 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00619385's enrollment target sits among peer trials
25 1495th of 2000 higher than 481 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01166854 · 25 participants
Characterization of Familial Myopathy and Paget Disease of Bone
- NCT01913106 · 25 participants · Phase 1
HSV-tk + Valacyclovir Therapy in Combination With Brachytherapy for Recurrent Prostate Cancer
- NCT02138669 · 25 participants · NA
Intacs Prescription Inserts for Keratoconus Patients
- NCT02174549 · 25 participants · Phase 1
Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia